αααααβααΎα688235 β’ SHA
add
BeOne Medicines AG
234.86Β₯
24 ααααΆ, 3:00:09 PM ααααβααα +8 · CNY · SHA · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
αα·αααΈαα»α
234.32Β₯
α
αααααααααααα
229.98Β₯ - 237.68Β₯
α
ααααααα½αααααΆαα
α»αααααα
213.33Β₯ - 346.00Β₯
ααΎαβαα»αβααΈααααΆα
259.84Β αααΈααΆα CNY
ααα ααα½αααΌαααααα
3.55Β ααΆα
α’αα»ααΆα P/E
239.65
αα·αααααβααΆαααΆα
-
ααΆααααααΌαα
αααα
SHA
αααα»αβααααααΆαβ
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
| (USD) | ααααΌ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌα | 1.50Β αααΈααΆα | 32.84% |
α
αααΆαααααα·ααααα·ααΆα | 1.17Β αααΈααΆα | 11.85% |
α
αααΌααα»ααα | 66.50Β ααΆα | 143.79% |
ααααΆααα
αααααα»ααα | 4.44 | 132.96% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | 0.58 | β |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | 219.47Β ααΆα | 822.86% |
α’ααααΆαααααααααΆαααααα·αααααΆα | 55.44% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
| (USD) | ααααΌ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 4.55Β αααΈααΆα | 73.08% |
ααααααααα»α | 8.19Β αααΈααΆα | 38.30% |
ααΆαααα½ααα»αααααΌαααα»α | 3.83Β αααΈααΆα | 47.85% |
ααΌαβααααα»α | 4.36Β αααΈααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 110.94Β ααΆα | β |
ααααααααααΉαααααα
| 5.96 | β |
ααα
ααααααΎαααααα | 5.85% | β |
ααα
ααααααΎααΎααα»α | 8.73% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
| (USD) | ααααΌ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌααα»ααα | 66.50Β ααΆα | 143.79% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | 417.35Β ααΆα | 455.28% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -38.34Β ααΆα | 59.05% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | 96.93Β ααΆα | 2,243.07% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | 499.10Β ααΆα | 768.32% |
ααα αΌαααΆα
αααααΆααααααα | 385.44Β ααΆα | 9,151.22% |
α’αααΈ
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
ααΆααααααΎαα‘αΎα
28 αα»ααΆ 2010
αααααβαααααΆα
αα»ααααα·α
12,000
